The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after multi-agent chemotherapy.
Please note that following on from advice received from the company and at their request NICE has suspended this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.